Cancer Localization in the Prostate with F-18 Fluorocholine Positron Emission Tomography
Abstract
The project evaluated fluorine-18 (18F-) fluorocholine positron emission tomography (PET) as an imaging technique for delineating malignancy in the prostate gland. The technique measures tissue metabolism of fluorocholine, a substrate that is preferentially metabolized by cancer cells due to malignant over-expression of the choline transporter and choline kinase enzyme. Based on this measurement, it was proposed that cancerous tissue can be differentiated from benign tissue in the prostate. Project Scope: Men with prostate cancer undergoing radical prostatectomy surgery underwent pre-operative PET scanning to measure fluorocholine uptake in the prostate gland. Imaging results were compared to histopathologic analyses of the prostatectomy specimen to determine the accuracy of prostate cancer sextant localization based on measured fluorocholine uptake. Recruitment of human subjects for this project was completed in 2008. A final one-year no-cost extension for a period of 20 December 2008 to 19 December 2009 is requested in order to complete final immunohistochemical analysis (proliferation index assays) of prostate specimens at the Armed Forces Institute of Pathology. Two subsequent research projects have been initiated based on the results of the current project. One project is a collaboration to develop clinically relevant image analysis tools for measuring the kinetics of 18F-fluorocholine activity in the prostate gland using PET/CT. The second project is a clinical trial proposal to assess treatment responses using 18F-fluorocholine PET/CT in clinically advanced prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 15, 2009
- Accession Number
- ADA500602
Entities
People
- Gregory Thibault
- Isabel A. Isabel
- Marc N. Coel
- Richard Stack
- Sandi A. Kwee
Organizations
- The Queen's Medical Center